NRG Oncology trial sets new standard regimen for women with uterine carcinosarcomas

(NRG Oncology) Results from the phase III NRG Oncology clinical trial GOG 0261 comparing paclitaxel plus carboplatin (PC) to paclitaxel plus ifosfamide (PI) in women with stage I-IV, recurrent carcinosarcoma of the uterus or ovary, indicate that the PC combination treatment should be considered a standard of care for this patient population.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news